Sun, May 16, 2021
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

The Corona Fighters Report 55: Asset managers who delivered in the downturn

Monday, July 13, 2020

Bailey McCann, Opalesque New York:

This is our regular report on hedge funds and alternative asset managers who are successfully protecting assets and outperforming the markets during the first months of 2020.

Biomedical companies continue to outperform

Vista Point Capital's flagship biotech fund - Parallax Biomedical Fund was up 2% (est.) in June and is up 11.7% year to date through June 30th. The fund was also up in Q1 2020 and ended 2019 up 54.20% following strong activity in the sector.

Biomedical companies have outperformed in recent months as the demand for covid-related solutions heats up alongside a growing demand for biomedical services overall. Biomedical companies like Moderna, for example, are working on a potential vaccine for Covid-19. The US government's Operation Warp Speed, which provides funding to fastrack the development of a coronavirus vaccine, provided a significant capital injection to a group of biomedical companies that could begin work on a coronavirus vaccine immediately. Most of that funding went to large-cap biomedical companies, but small-cap biomedical companies with products in the pipeline often become targets for acquisition by large-cap companies in this sector.

Parallax makes investments in small-cap biotechnology and medical technology companies. The investment team is typically looking for companies that have later stage products in development or those that have low valuations with room to grow. The strategy takes advantage of the high barriers to entry for biomedical companies. The field is complex and inefficient which lead to dislocations in the stocks that can be beneficial for opportunistic traders. The fund runs a concentrated portfolio of 20-25 core positions and invests in both US and European companies.

Vista Point is led by Marc Pentopolous. Pentopolous founded Katana Pharmaceuticals and has decades of experience in medical technology, drug development, and finance. He also led Emerging Growth Management's medical technology strategy.

Marc Pentopolous will be a presenter in our fourth Corona Fighters webinar discussing the biomedical sector and other portfolio diversifiers. Registration is free.

View prior reports: Report 54

Webinar: The Corona Fighters Episode 4

Meet five more asset managers who delivered during the meltdown.

Time: Tuesday, July 21st, 10 am EST
Details and registration:

New eBook: The Corona Fighters COLLECTION - A Handbook for Investors

200+ funds that were up or protected assets in Q1 2020: A Compendium of Opalesque Corona Fighters Report #1 to Report #52

Download here:


Disclaimer: This is not investment advice. Opalesque has not verified this information and gives no warranty of accuracy or completeness. Past performance is not indicative of future results. See our Terms & Conditions for more information.



Meet 15 fund managers and learn how and why their strategies delivered positive returns and/or protected capital during the Corona led market meltdown! Each webinar lasts an hour and features five managers.

"The whole Corona Fighters program has been extremely educational for me and a great opportunity to learn more about hedge funds and compare/contrast their approaches." (Single Family Office Principal)

Video replays of Opalesque's past webinars can be found here:

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. U.S.: Hedge funds facing Biden tax threat grab toehold in Puerto Rico[more]

    From Bloomberg: With Democrats pushing for higher taxes on the richest Americans to fund President Joe Biden's infrastructure and climate initiatives, hedge fund managers are taking refuge in Puerto Rico. ExodusPoint Capital Management and Millennium Management have established subsidiaries on t

  2. SPACs: SoftBank-backed Better to go public in $7.7bn SPAC deal, Turmoil in the SPAC market, SPACs that raise a lot of money will struggle to find startups, Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal[more]

    SoftBank-backed Better to go public in $7.7bn SPAC deal From PE Insights: SoftBank Group Corp-backed Better HoldCo said on Tuesday it will go public through a merger with a blank-check firm sponsored by investment firm Novator Capital, valuing the mortgage startup at $7.7bn. As p

  3. Hedge fund Tiger Global beats out Silicon Valley VCs, invests in 110 startups so far[more]

    From Business Insider: Tiger Global, a $65 billion hedge fund, is squeezing out venture capital firms to invest in startups. The company has taken part in 110 startup financings so far in 2021, according to PitchBook. Venture capitalists say its speed and sky-high valuations lead to its success

  4. SPACs: Why the 'SPAC Mafia' hedge funds aren't worried about SEC regulation, Bill Ackman's cagey SPAC update sends shares soaring as investors dream up a mega-deal, Arqit raising $400m with a SPAC to launch quantum encryption satellites in 2023[more]

    Why the 'SPAC Mafia' hedge funds aren't worried about SEC regulation From Business Insider: After a yearlong bout of SPAC mania, the red-hot market for blank-check companies is cooling down as regulators direct their attention to it. March was a record-breaking month for special-purpose

  5. Private strategies pay off for Tiger Global, other hedge fund titans[more]

    From Institutional Investor: Hedge funds' strategies to invest in private markets have been driving returns at a number of firms this year. Third Point, Greenlight, Tiger Global, and Maverick received big boosts in the first quarter from their private investing strategies. That shouldn't be a